Literature DB >> 12900218

Targeting cancer cells by exploiting their resistance.

Mikhail V Blagosklonny1.   

Abstract

Cancer cells are intrinsically resistant to growth arrest and can further acquire multidrug resistance. Current approaches to this problem are intended to reverse, overcome or prevent the drug resistance. However, the resistance of cancer cells can be exploited to kill resistant cells selectively, while sparing sensitive normal cells. As the simplest example, multidrug-resistant cells pump out protectors, such as pharmacological inhibitors of apoptosis. A sequence of at least two agents must include an exclusive protector, which is ineffective in resistant cancer cells, and an inclusive cytotoxic drug, which kills unprotected cells. By abolishing several dose-limiting side effects of chemotherapy, this strategy provides a means to treat selectively most deranged, aggressive and resistant cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900218     DOI: 10.1016/s1471-4914(03)00111-4

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  11 in total

1.  Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway.

Authors:  Yanjie You; Haijun Li; Jiongyu Chen; Xin Qin; Yonggang Ran
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

2.  Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN).

Authors:  Djamila Ouaret; Annette K Larsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  A novel bisindole-PBD conjugate causes DNA damage induced apoptosis via inhibition of DNA repair pathway.

Authors:  Pranjal Sarma; M Janaki Ramaiah; Ahmed Kamal; Utpal Bhadra; Manika Pal Bhadra
Journal:  Cancer Biol Ther       Date:  2014-07-10       Impact factor: 4.742

4.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06

5.  Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres.

Authors:  M Janaki Ramaiah; Sncvl Pushpavalli; G Rama Krishna; Pranjal Sarma; Debasmita Mukhopadhyay; Ahmed Kamal; Utpal Bhadra; Manika Pal Bhadra
Journal:  Cancer Cell Int       Date:  2011-04-25       Impact factor: 5.722

6.  NCI's provocative questions on cancer: some answers to ignite discussion.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2011-12

7.  Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.

Authors:  Xiao-Kun Wang; Kenneth Kin Wah To; Li-Yan Huang; Jing-Hong Xu; Ke Yang; Fang Wang; Zhen-Cong Huang; Sheng Ye; Li-Wu Fu
Journal:  Oncotarget       Date:  2014-12-15

Review 8.  Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.

Authors:  Jinglu Wang; Nicole Seebacher; Huirong Shi; Quancheng Kan; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-07-12

9.  Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-12

10.  Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

Authors:  Michaela Aichler; Martin Motschmann; Uta Jütting; Birgit Luber; Karen Becker; Katja Ott; Florian Lordick; Rupert Langer; Marcus Feith; Jörg Rüdiger Siewert; Axel Walch
Journal:  Oncotarget       Date:  2014-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.